168 filings
Page 3 of 9
6-K
sjpnunnw36lkx
16 May 23
CENTOGENE Reports Full Year 2022 Financial Results
5:43pm
6-K
x6eh kxiydp
4 May 23
Second Amendment to Loan and Security Agreement
4:18pm
NT 20-F
15st916 b4
28 Apr 23
Notice of late annual filing (foreign)
7:27am
6-K
xxtq428k6 xs57
28 Apr 23
CENTOGENE Receives Nasdaq Non-Compliance Notice
7:25am
6-K
tfplxxd lfzrvrny
26 Apr 23
CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics Pipeline
8:16am
6-K
lti 5b9ft0f
12 Apr 23
CENTOGENE Launches NEW CentoGenome®, World’s Most Comprehensive Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases
6:30am
6-K
pdamjb16y7d
11 Apr 23
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
6:30am
6-K
6tjj9fj8x otdqrt
28 Mar 23
Current report (foreign)
6:30am
6-K
ote7jb3ioe9
14 Mar 23
Current report (foreign)
8:41am
6-K
qw31b5ld4bvmwv
9 Mar 23
CENTOGENE Appoints Ian Rentsch as Chief Commercial Officer and General Manager - Pharma
6:30am
6-K
bdftfbr tlkzmyey8h
21 Feb 23
Current report (foreign)
6:31am
6-K
2dl8 hxtk0
7 Feb 23
Current report (foreign)
8:00am
6-K
wz0vk4 t96vjc1
30 Jan 23
CENTOGENE Announces Executive Appointment
4:30pm
6-K
2jram dx4
19 Jan 23
CENTOGENE Announces Departure From Executive Team
8:01am
6-K
y7ckzw7xfp1u8lf9cw
10 Jan 23
Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics
8:00am
6-K
6xdt272uwb
9 Jan 23
Current report (foreign)
8:30am
6-K
gd94d1fspiknvx363wwh
9 Jan 23
Premier Research and CENTOGENE Launch Strategic Partnership to Accelerate and De-Risk Rare Disease Clinical Development
8:03am
6-K
oq0312ne0q
22 Dec 22
CENTOGENE Reports Second Quarter and First Half 2022 Financial Results
4:13pm
6-K
jbx2uko
16 Dec 22
CENTOGENE Receives Nasdaq Non-Compliance Notice
4:33pm